Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Rhea-AI Summary

Immix Biopharma, Inc. has announced the pricing of an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share, with expected gross proceeds of approximately $15 million. The company intends to use the net proceeds for NXC-201 clinical trials, working capital, and general corporate purposes.

Insights

Financial Analyst

The pricing of Immix Biopharma's public offering at $2.71 per share, with an expected gross proceeds of approximately $15 million, is a strategic financial move that warrants a closer examination. The capital raise through an underwritten public offering is a common method for biopharmaceutical companies to fund their operations and research activities. The use of the net proceeds for NXC-201 clinical trials, working capital and general corporate purposes is a clear indicator of the company's intention to advance its pipeline and maintain operational stability.

Investors should consider the dilutive effect of the additional shares on the existing shareholder value. The offering's success and the subsequent use of funds could potentially lead to share price volatility, depending on the market's perception of the company's growth prospects and the progress of its clinical trials. The option granted to the underwriters to purchase additional shares could further impact the stock's supply-demand dynamics.

Market Research Analyst

Immix Biopharma's decision to execute a public offering can be seen as a response to the capital-intensive nature of the biopharmaceutical industry. Raising funds through the equity market is a testament to the company's proactive approach to securing financial resources necessary for continued research and development. The market's reception of this offering will be influenced by the company's current valuation, investor sentiment towards the biopharmaceutical sector and the perceived potential of NXC-201.

It is also important to consider the competitive landscape and the company's position within it. The success of the NXC-201 clinical trials could be a significant differentiator for Immix Biopharma, potentially positioning it favorably against competitors. The timing of the offering and the market conditions at the time of closing will also play crucial roles in the overall impact on the company’s market performance.

Medical Research Analyst

The allocation of funds towards the NXC-201 clinical trials is a critical component of Immix Biopharma's strategy. Clinical trials are the cornerstone of drug development in the biopharmaceutical industry and the progression of NXC-201 will be closely monitored by stakeholders. The outcome of these trials will not only influence the company's future revenue streams and market position but also have implications for patients awaiting novel treatments.

Understanding the science behind NXC-201 and its potential therapeutic benefits is essential for evaluating the investment's risk profile. The drug's efficacy, safety profile and market demand, along with regulatory hurdles, will determine the long-term return on investment. The company's ability to execute on its clinical development plan and navigate the regulatory landscape will be pivotal in realizing the value of this capital infusion.

LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock. ImmixBio has granted the underwriters a 30-day option to purchase up to 783,970 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on February 8, 2024, subject to the satisfaction of customary closing conditions.

Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the offering.

The gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for NXC-201 clinical trials, working capital and general corporate purposes.

The offering is being made pursuant to an effective “shelf” registration statement on (File No. 333-269100) previously filed with the Securities and Exchange Commission (the “SEC”) on January 3, 2023, and declared effective by the SEC on January 11, 2023. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering, may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, New York 10007, by phone at (929) 833-1246 or by email at info@titanpartnersgrp.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing cell therapies in autoimmune disease. The Company’s lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, currently being evaluated in an ongoing Phase 1b/2a NEXICART-1 (NCT04720313) clinical trial.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding ImmixBio's expectations on the timing and completion of the offering and the anticipated use of proceeds therefrom. The offering is subject to customary closing conditions and there can be no assurance as to whether or when the offering may be completed.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed under the caption "Risk Factors" in the preliminary prospectus supplement related to the offering. These forward-looking statements speak only as of the date hereof. ImmixBio disclaims any obligation to update these forward-looking statements, except as required by applicable law.

Contact Information
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

FAQ

What is the offering price of Immix Biopharma, Inc.'s common stock?

The offering price of Immix Biopharma, Inc.'s common stock is $2.71 per share.

How many shares are included in the underwritten public offering?

The underwritten public offering includes 5,535,055 shares of Immix Biopharma, Inc.'s common stock.

What are the expected gross proceeds from the offering?

The expected gross proceeds from the offering are approximately $15 million.

What are the intended uses of the net proceeds from the offering?

The net proceeds from the offering will be used for NXC-201 clinical trials, working capital, and general corporate purposes.